Checkpoint Therapeutics, Inc.
CKPT
$4.04
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 164.04% | 42.10% | |||
| Gross Profit | -164.04% | -43.41% | |||
| SG&A Expenses | 257.95% | 50.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 196.47% | 44.83% | |||
| Operating Income | -196.47% | -45.72% | |||
| Income Before Tax | -197.17% | -45.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -197.17% | -45.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -197.17% | -45.80% | |||
| EBIT | -196.47% | -45.72% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -178.57% | -23.44% | |||
| Normalized Basic EPS | -178.50% | -23.49% | |||
| EPS Diluted | -178.57% | -23.44% | |||
| Normalized Diluted EPS | -178.50% | -23.49% | |||
| Average Basic Shares Outstanding | 6.66% | 18.14% | |||
| Average Diluted Shares Outstanding | 6.66% | 18.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||